Impact of the intervention on child LAZ, stunting and ln serum AFB1-lysine adduct levels
| Intervention | Control | Impact estimate (95% CI) | P values* | n | |
| Primary outcomes | |||||
| LAZ (endline) | −1.68±1.08 | −1.59±1.27 | −0.010 (−0.165 to 0.146) | 0.551 | 881 |
| Stunting (endline) | 39.26 | 35.71 | 0.015 (−0.052 to 0.082) | 0.671 | 881 |
| Ln serum AFB1-lysine adduct level (endline)† | 1.78±1.28 | 2.01±1.37 | −0.273 (−0.547 to 0.001) | 0.025 | 798 |
| Secondary outcomes | |||||
| LAZ (midline) | −1.17±1.13 | −1.32±1.24 | 0.160 (−0.009 to 0.33) | 0.032 | 613 |
| Stunting (midline) | 20.00 | 26.57 | −0.066 (−0.125 to −0.007) | 0.015 | 613 |
| Ln serum AFB1-lysine adduct level (midline)‡ | 1.54±1.17 | 1.60±1.21 | −0.062 (−0.299 to 0.175) | 0.302 | 524 |
*One-sided p values are shown.
†Sample sizes for serum aflatoxin were 436 and 362 in the intervention and control arms at endline, respectively. Absolute AFB1-lysine adduct level were 14.79±30.24 pg/mg albumin in the intervention arm and 22.19±58.1 pg/mg albumin in the control arm.
‡Sample sizes for serum aflatoxin were 279 and 245 in the intervention and control arms at midline, respectively. Absolute AFB1-lysine adduct level were 9.83±18.62 pg/mg albumin in the intervention arm and 16.12±71.94 pg/mg albumin in the control arm.
AFB1, aflatoxin B1; LAZ, length-for-age Z-score.